CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
Mitoquinone/mitoquinol mesylatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05381454
NCT05381454Phase 2Completed
CompareCT.gov

An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate as Prophylaxis for Development of Severe Viral Illness

University of California, Los Angeles·interventional·Posted May 19, 2022·Updated Dec 16, 2025

In Brief

A Phase 2 clinical trial evaluating Mitoquinone/mitoquinol mesylate for Respiratory Viral Infection and 2 related conditions. Completed, enrolled 80 participants across 1 site.

Detailed Summary

Open label clinical trial of persons (adults) that will determine the safety and efficacy of the diet supplement oral mitoquinone/mitoquinol mesylate (Mito-MES) to prevent the development and progression of severe viral infections like COVID-19 after high-risk exposure to a person with possible respiratory viral infection such as SARS-CoV-2 infection in persons who will receive Mito-MES compared to persons who will not receive Mito-MES (controls).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRespiratory Viral Infection, Antiviral Treatment, COVID-19
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedMay 19, 2022
Enrollment StartApr 28, 2022
Primary CompletionMay 9, 2023
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 4.1 years ago

Interventions

Mitoquinone/mitoquinol mesylatedrug

Mitoquinone/mitoquinol mesylate